ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results

Data ReadoutpositivePositive

AI Analysis

Summary

ProMIS Neurosciences reported positive interim safety results from an Alzheimer's disease trial, leading to a rise in share price. The announcement reflects favorable safety profile data from the ongoing study.

Clinical Trial Data

Phase

interim

Outcome Details

Positive interim safety results

Importance:6/10

Sentiment:

0.70

Alzheimer'sclinical trialsafety datainterim results

Related Companies

$PMN

Read the original article

Published by yahoo_finance on July 28, 2026 12:25 PM

Read Original